A Critical Juncture for the UK’s Vaccines Industry
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Address: Janssen, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom
Tel: +44 (0) 1494 567567
Web: http://www.janssen.co.uk/
In 1947, Ortho Pharmaceuticals was brought into the Johnson & Johnson group of companies and set up a UK base in Lane End, Buckinghamshire.
Johnson & Johnson’s pharmaceutical interests expanded over the next decades with the addition of the Swiss company Cilag Chemie in 1959 and the Belgian company Janssen Pharmaceutica in 1961. Both of these companies had grown from small research laboratories into successful multinationals.
Ortho moved to a site in Saunderton, Buckinghamshire in the early 1950s. Janssen established its first British offices in Marlow, Buckinghamshire, in 1974 and moved to Grove in Oxfordshire a decade later.
Ortho became Ortho Cilag in 1982 and then Cilag in 1988. On 1st January 1995, Cilag and Janssen merged to become Janssen-Cilag Ltd and all operations were transferred to the Saunderton site. In May 2008, the company moved to new offices in High Wycombe.
In September 2000, Ortho Biotech was established, a company specialising in treatments for conditions such as renal disease and cancer.
Tibotec was established in 1994 as a drug discovery laboratory, it evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for infectious diseases. In April 2002, Tibotec was acquired by Johnson & Johnson and became a division of Janssen-Cilag.
In 2010, Janssen-Cilag became Janssen and now employs more than 400 people. Its head office is in High Wycombe, Buckinghamshire and also has an office in Dublin.
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen employs more than 400 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Janssen has one of the strongest development pipelines in the industry with research now focusing on five key areas. These key areas are: neuroscience, oncology, immunology, metabolism and infectious diseases.
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
See our Cookie Privacy Policy Here
